Clinical Trials Logo

Sclerosing Cholangitis clinical trials

View clinical trials related to Sclerosing Cholangitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05187312 Not yet recruiting - Pancreatic Cancer Clinical Trials

Registry for Advanced Endoscopy

ERDB
Start date: January 14, 2022
Phase:
Study type: Observational [Patient Registry]

Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract

NCT ID: NCT02424175 Completed - Clinical trials for Sclerosing Cholangitis

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

Start date: February 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label single-arm pilot study to measure the safety, microbiological and clinical impacts of Fecal Microbiota Transplantation (FMT) in patients with Primary Sclerosing Cholangitis (PSC). The investigators will prospectively enroll 10 PSC patients Stage 1 and 2 who also have concurrent inflammatory bowel disease Donor Stool from one healthy donor will be obtained from OpenBiome. OpenBiome is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use

NCT ID: NCT01988506 Completed - Clinical trials for Rheumatoid Arthritis

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

TRANSREG
Start date: January 6, 2014
Phase: Phase 2
Study type: Interventional

TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be performed. Extensive biological- and immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct processes responsible for the breakdown of immunological tolerance in these pathologies and (ii) to discover potential biomarkers of the IL2 response.

NCT ID: NCT01556555 Completed - Clinical trials for Sclerosing Cholangitis

Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)

Start date: September 2008
Phase:
Study type: Observational

This study aim to prospectively evaluate the clinical utility of Spyglass in sclerosing cholangitis patients undergoing endoscopic retrograde cholangiopancreaticography (ERCP). Fifty patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP from September 2008 and onwards will be investigated with peroral cholangioscopy using Spyglass direct visualization system. Clinical data on all patients will be collected at time of the ERCP including information on the Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), serum liver function tests and indication for ERCP. A structured data collection form including information on Majoie Score, macroscopic features of the bile ducts at cholangioscopy, quality of the investigation, technical difficulties, and an overall judgment of whether any abnormalities observed were benign or malignant was completed by the endoscopist in conjunction with the procedure.